Stay updated on Nivolumab and Relatlimab in MMRd Cancers Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study criteria and the principal investigator's name, while retaining key drug information and collaborators.SummaryDifference24%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check110 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Nivolumab and Relatlimab in MMRd Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.